Development of domain-selective angiotensin I-converting enzyme inhibitors

Annals of the New York Academy of Sciences

Volumn 1056, Issue , 2005, Pages 160-175

  Redelinghuys, Pierre ^a   Nchinda, Aloysius T ^a   Sturrock, Edward D ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Angiotensin I converting enzyme; Domain selectivity; Drug design; Inhibitors

Indexed keywords

ANGIOTENSIN; BRADYKININ; CAPTOPRIL; CARBENOID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENALAPRILAT; FOSINOPRIL; HYDROXAMIC ACID DERIVATIVE; LISINOPRIL; PHENYLALANINE DERIVATIVE; PHOSPHINIC ACID DERIVATIVE; RAMIPRILAT; RXP 407; RXP A380; SILANE DERIVATIVE; SILANEDIOL DERIVATIVE; UNCLASSIFIED DRUG; [HYDROXYL (4 PHENYLBUTYL)PHOSPHINYL]ACETYLPROLINE;

AMINO TERMINAL SEQUENCE; BLOOD PRESSURE; CARBOXY TERMINAL SEQUENCE; CARDIOVASCULAR DISEASE; CONFERENCE PAPER; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG STRUCTURE; DRUG SYNTHESIS; ELECTROLYTE BALANCE; ENZYME INHIBITION; ENZYME SUBSTRATE; HOMEOSTASIS; NONHUMAN; PROTEIN DOMAIN; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; STRUCTURE ANALYSIS;

EID: 29744445643     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1352.035     Document Type: Conference Paper

References (74)

1. KEARNEY, P.M., M. WHELTON, K. REYNOLDS, et al. 2005. Global burden of hypertension: analysis of worldwide data. Lancet 365: 217-223.
2. CARRETERO, O.A. & S. OPARIL. 2000. Essential hypertension. Part I: definition and etiology. Circulation 101: 329-335.
3. RAWLINGS, N.D., D.P. TOLLE & A.J. BARRETT. 2004. Evolutionary families of peptidase inhibitors. Biochem. J. 378: 705-716.
4. RAWLINGS, N.D., D.P. TOLLE & A.J. BARRETT. 2004. MEROPS: the peptidase database. Nucleic Acids Res. 32: D160-D164.
5. EHLERS, M.R.W. & J.F. RIORDAN. 1989. Angiotensin-converting enzyme: new concepts concepts concerning its biological role. Biochemistry 28: 5311-5318.
6. CORVOL, P., T.A. WILLIAMS & F. SOUBRIER. 1995. Peptidyl dipeptidase A: angiotensin I-converting enzyme. Methods Enzymol. 248: 283-305. Academic Press.
7. SOUBRIER, F., F. ALHENC-GELAS, C. HUBERT, et al. 1988. Two putative active centers in human angiotensin I-converting enzyme revealed by molecular cloning. Proc. Natl. Acad. Sci. USA 85: 9386-9390.
8. SOUBRIER, F., C. HUBERT, P. TESTUT, et al. 1993. Molecular biology of the angiotensin I-converting enzyme: I. Biochemistry and slructure of the gene. J. Hypertens. 11: 471-476.
9. HOOPER, N.M., E.H. KARRAN & A.J. TURNER. 1997. Membrane protein secretases. Biochem. J. 321: 265-279.
10. WEI, L., F. ALHENC-GELAS, P. CORVOL & E. CLAUSER. 1991. The two homologous domains of human angiotensin I-converting enzyme are both catalytically active. J. Biol. Chem. 266: 9002-9008.
11. JASPARD, E., L. WEI & F. ALHENC-UELAS. 1993. Differences in the properties and enzymatic specificities of the two active sites of angiotensin I-converting enzyme (kininase 11). J. Biol. Chem. 268: 9496-9503.
12. EHLERS, M.R.W., Y.-N.P. CHEN & J.F. RIORDAN. 1991. Purification and Characterization of recombinant human testis angiotensin-Converting Enzyme Expressed in Chinese hamster ovary cells. Protein Exp. Purif. 2: 1-9.
13. HAGAMAN, J.R., S.S. MOYER, E.S. BACHMAN, et al. 1998. Angiotensin-converting enzyme and male fertility. Proc. Natl. Acad. Sci. USA 95: 2552-2557.
14. KONDOH, G., H. TOJO, Y. NAKATANI, et al. 2005. Angiotensin-converting enzyme is a GPI-anchored protein releasing factor crucial for fertilization. Nat. Med. 11: 160-166.
15. EHLERS, M.R.W. & J.F. RIORDAN. 1990. Angiotensin-Converting Enzyme: Biochemistry and Molecular Biology. Hypertension: Palhophysiology, Diagnosis, and Management Chapt. 76: 1217-1231. Raven Press. New York.
16. RIPKA, J.E., J.W. RYAN, F.A. VALIDO, et al. 1993. N-glycosylation of forms of angiotensin converting enzyme from four mammalian species. Biochem. Biophys. Res. Commun. 196: 503-508.
17. YU, X.C., E.D. STURROCK, Z. Wu, et al. 1997. Identification of N-linked glycosylation sites in human testis angiotensin-converting enzyme and expression of an active deglycosylated form. J. Biol. Chem. 272: 3511-3519.
18. NAQVI, N., K. LIU, R.M. GRAHAM & A. HUSAIN. 2005. Molecular basis of exopeptidase activity in the C-terminal domain of human angiotensin 1-converting enzyme. J. Biol. Chem. 280: 6669-6675.
19. CORVOL, P., M. EYRIES & F. SOUDRIER. 2004. In Handbook of Proteolytic Enzymes. A.J. Barrett, N.D. Rawlings & J.F. Woessner. Eds. :332-346. Academic Press Inc. New York.
20. BAUDIN, B. 2002. New aspects on anaiotensin-converting enzyme: from gene to disease. Clin. Chem. Lab. Med. 40: 256-265.
21. VAN ESCH, J.H., B. TOM, V. DIVE, et al. 2005. Selective angiotensin-converting enzyme C-domain inhibition is sufficient to prevent angiotensin I-induced vasoconstriction. Hypertension 45: 120-125.
22. ESTHER, C.R., E.M. MARINO, T.E. HOWARD, et al. 1997. The critical role of tissue angiotensin-converting enzyme as revealed by gene targeting in mice. J. Clin. Invest. 99: 2375-2385.
23. FUCHS, S., H.D. XIAO, J.M. COLE, et al. 2004. Role of the N-terminal catalytic domain of angiotensin-converting enzyme investigated by targeted inactivation in mice. J. Biol. Chem 279: 15946-15953.
24. FERNANDEZ, J.H., M.A. HAYASHI, A.C. CAMARGO & G. NESHICH. 2003. Structural basis of the Iisinopril-binding specificity in N- and C-domains of human somatic ACE. Biochem. Biophys. Res. Commun. 308: 219-226.
25. OBA, R., A. IGARASHI, M. KAMATA, et al. 2005. The N-terminal active centre of human angiotensin-converting enzyme degrades Alzheimer amyloid beta-peptide. Eur. J. Neurosci. 21: 733-740.
26. VORONOV, S., N. ZUEVA, V. ORLOV, et al. 2002. Temperature-induced selective death of the C-domain within angiotensin-converting enzyme molecule. FEBS Lett. 522: 77-82.
27. ANDUJAR-SANCHEZ, M., A. CAMARA-ARTIGAS & V. JARA-PEREZ. 2004. A calorimetric study of the binding of Iisinopril, enalaprilat and captopril to angiotensin-converting enzyme. Biophys. Chem. 111: 83-189.
28. CUSHMAN, D.W., H.S. CHEUNG. E.F. SABO & M.A. ONDETTI. 1977. Design of potent competitive inhibitors of angiotensin-converting enzyme. Carboxyalkanoyl and mercaptoalkanoyl amino acids. Biochemistry 16: 5484-5491.
29. ONDETTI, M.A., B. RUBIN & D.W. CUSHMAN. 1977. Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents. Science 196:441-444.
30. CUSHMAN, D.W. & M.A. ONDETTI. 1999. Design of angiotensin converting enzyme inhibitors. Nat. Med. 5: 1110-1113.
31. FERREIRA, S.H. & M. ROCHA E SILVA. 1965. Potentiation of bradykinin and eledoisin by BPF (bradykinin potentiating factor) from Bothrops jararaca venom. Experientia 21: 347-349.
32. FERREIRA, S.H., D.C. BARTELT & L.J. GREENE. 1970. Isolation of bradykinin-potentiating peptides from Bothrops jararaca venom. Biochemistry 9: 2583-2593.
33. FERREIRA, S.H., L.H. GREENE, V.A. ALABASTER, et al. 1970. Activity of various fractions of bradykinin potentiating factor against angiotensin I converting enzyme. Nature 225: 379-380.
34. HAYASHI, M.A. & A.C. CAMARGO. 2005. The bradykinin-potentiating peptides from venom gland and brain of Bothrops jararaca contain highly site specific inhibitors of the somatic angiotensin-converting enzyme. Toxicon 45: 1163-1170.
35. PATCHETT, A. A., E. HARRIS, E. W. TRISTRAM, et al. 1980. A new class of angiotensin-converting enzyme inhibitors. Nature 288: 280-283.
36. PATCHETT, A.A. & E.H. CORDES. 1985. The design and properties of N-carboxyalkyl-dipeptide inhibitors of angiotensin-converting enzyme. Adv. Enzymol. Relat. Areas Mol. Biol. 57: 1-84.
37. BICKET, D.P. 2002. Using ACE inhibitors appropriately. Am. Fam. Physician 66: 461-468.
38. DICKSTEIN, K. & J. KJEKSHUS. 2002. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal trial in myocardial infarction with angiotensin ii antagonist losartan. Lancet 360: 752-760.
39. ADAM, A., M. CUGNO, G. MOLINARO, et al. 2002. Aminopeptidase P in individuals with a history of angio-oedema on ACE inhibitors. Lancet 359: 2088-2089.
40. MORIMOTO, T., T.K. GANDHI, J.M. FISKIO, et al. 2004. An evaluation of risk factors for adverse drug events associated with angiotensin-converting enzyme inhibitors. J. Eval. Clin. Pract. 10: 499-509.
41. DIVE, V., D. GEORGIADIS, M. MATZIARI, et al. 2004. Phosphinic peptides as zinc metalloproteinase inhibitors. Cell Mol. Life Sci. 61: 2010-2019.
42. NATESH, R., S.L. SCHWAGER, E.D. STURROCK & K.R. ACHARYA. 2003. Crystal structure of the human angiotensin-converting enzyme-Iisinopril complex. Nature 421: 551-554.
43. KIM, H.M., D.R. SHIN, O.J. YOO, et al. 2003. Crystal structure of Drosophila angiotensin I-converting enzyme bound to captopril and Iisinopril. FEBS Lett. 538: 65-70.
44. NATESH, R., S.L. SCHWAGER, H.R. EVANS, et al. 2004. Structural details on the binding of antihypertensive drugs captopril and enalaprilat to human testicular angiotensin I-converting enzyme. Biochemistry 43: 8718-8724.
45. TZAKOS, A.G. & I.P. GEROTHANASSIS. 2005. Domain-selective ligand-binding modes and atomic level pharmacophore refinement in angiotensin I converting enzyme (ACE) inhibitors. Chembiochemistry 6: 1089-1103.
46. DE LIMA, D.P. 1999. Synthesis of angiotensin-converting enzyme (ACE) inhibitors: An important class of antihypertensive drugs. Quimica Nova 22: 375-381.
47. KRAPCHO, J., C. TURK, D. W. CUSHMAN, et al. 1988. Angiotensin-converting enzyme inhibitors. Mercaptan, carboxyalkyl dipeptide, and phosphinic acid inhibitors incorporating 4-substituted prolines. J. Med. Chem. 31: 1148-1160.
48. DIVE, V., J. COTTON, A. YIOTAKIS, et al. 1999. RXP 407, a phosphinic peptide, is a potent inhibitor of angiotensin I converting enzyme able to differentiate between its two active sites. Proc. Natl. Acad. Sci. USA 96: 4330-4335.
49. GEORGIADIS, D., P. CUNIASSE, J. COTTON, et al. 2004. Structural determinants of RXPA380, a potent and highly selective inhibitor of the angiotensin-converting enzyme C-domain. Biochemistry 43: 8048-8054.
50. JUNOT, C., M.F. GONZALES, E. EZAN, et al. 2001. RXP 407, a selective inhibitor of the N-domain of angiotensin I-converting enzyme, blocks in vivo the degradation of hemoregulalory peptide acetyl-Ser-Asp-Lys-Pro with no effect on angiotensin 1 hydrolysis. J. Pharmacol. Exp. Then 297: 606-611.
51. GEORGIADIS, D., F. BEAU, B. CZARNY, et al. 2003. Roles of the two active sites of somatic angiotensin-converting enzyme in the cleavage of angiotensin I and bradykinin: insights from selective inhibitors. Circ Res. 93: 148-154.
52. CLIVE, D.L.J. & D.M. COLTART. 1998. Synthesis of the angiotensin-converting enzyme inhibitors (+/-)-A58365. Tetrahedron Lett.39: 2519-2522.
53. CLIVE, D.L.J., H. YANG & R.Z. LEWANCZUK. 2001. Synthesis and in vitro activity of a non-epimerizable analogue of the angiotensin-converting enzyme inhibitors A58365A. C. R. Acad. Sci. Paris. Chimie 4: 505-512.
54. REICHELT, A., S.K. BUR & S.F. MARTINS. 2002. Applications of vinylogous Mannich reactions: Total synthesis of the angiotensin-converting enzyme inhibitors (-)-A58365A. Tetrahedron 58: 6323-6328.
55. ALMQUIST, R.G., W.R. CHAO, M.E. ELLIS & H.L. JOHNSON, 1980. Synthesis and biological activity of a ketomethylene analogue of a tripeplide inhibitor of angiotensin converting enzyme. J. Med. Chem. 23: 1392-1398.
56. DEDDISH, P.A., B. MARCIC, H.L. JACKMAN, et al. 1998. N-domain-specific substrate and C-domain inhibitors of angiotensin-converting enzyme: angiotensin-(1-7) and keto-ACE. Hypertension 31: 912-917.
57. MEYER, R.F., E.D. NICOLAIDES. F.J. TINNEY. et al. 1981. Novel synthesis of (S)-1-[5-(benzoylamino)-1,4-dioxo-6-phenylhexyl]-L-proline and analogues: potent angiotensin converting enzyme inhibitors. J. Med. Chem. 24: 964-969.
58. ACHARYA, K.R., E.D. STURROCK, J.F. RIORDAN & M.R. EHLERS. 2003. Ace revisited: a new target for structure-based drug design. Nat. Rev. Drug Discov. 2: 891-902.
59. KIM, J., G. HEWITT, P. CARROLI, & S.M. SIEBURTH. 2005. Silanediol inhibitors of angiotensin-converting enzyme: synthesis and evaluation of four diastereomers of Phe[Si]Ala dipeptide analogues. J. Org. Chem. 70: 5781-5789.
60. SANDERSON, P.E. 1999. Small, noncovalent serine protease inhibitors. Med. Res. Rev. 19: 179-197.
61. BURSAVICH, M.G. & D.H. RICH. 2002. Designing non-peptide peptidomimetics in the 21st century: inhibitors targeting conformational ensembles. J. Med. Chem. 45: 541-558.
62. MUTAHI, M., T. NITTOLI, L. GUO & S.M. SIEBURTH. 2002. Silicon-based metalloprotease inhibitors: synthesis and evaluation of silanol and silanediol peptide analogues as inhibitors of angiotensin-converting enzyme. J. Am. Chem. Soc. 124: 7363-7375.
63. KIM, J. & S.M. SIEBURTH. 2004. Silanediol peptidomimetics. Evaluation of four diastereomeric ACE inhibitors. Bioorg. Med. Chem. Lett. 14: 2853-2856.
64. CHOO, H.-Y. P. ., K.-H. PEAK, J. PARK, et al. 2000. Design and synthesis of α.β-unsaturated carbonyl compounds as potential ACE inhibitors. Eur. J. Med. Chem. 35: 643-648.
65. BERSANETTI, P.A., M.C. ANDRADE, D.E. CASARINI, et al. 2004. Positional-scanning combinatorial libraries of fluorescence resonance energy transfer peptides for defining substrate specificity of the angiotensin I-converting enzyme and development of selective C-domain substrates. Biochemistry 43: 15729-15736.
66. HANESSIAN, S., U. REINHOLD, M. SAULNIER & S. CLARIDGE. 1998. Probing the importance of spacial and conformational domains in captopril analogues for angiotensin-converting enzyme activity. Bioorg. Med. Chem. Lett. 8: 2123-2128.
67. SUBISSI, A., M CRISCUOLI, G. SARDELLI, et al. 1992. Pharmacology of idrapril: a new-class of angiotensin converting enzyme inhibitors. J. Cardiovasc. Pharmacol. 20: 139-146.
68. TURBANTI, L., G. CERBAI, C. DI BUGNO, et al. 1993. 1,2- Cyclomethylenecarboxylic monoamide hydroxamic derivatives. A novel class of non-amino acid angiotensin converting enzyme inhibitors. J. Med. Chem. 36: 699-707.
69. McFARLANE, S.I., A. KUMAR & J.R. SOWERS. 2003. Mechanisms by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease. Am. J. Cardiol. 91: 30H-37H.
70. SATOH, S., Y. UEDA, N. SUEMATSU, et al. 2003. Beneficial effects of angiotensin-converting enzyme inhibition on sarcoplasmic reticulum function in the failing heart of the Dahl rat. Circ. J. 67: 705-711.
71. HAMDI, H. K. & R. CASTELLON. 2003. ACE inhibition actively promotes cell survival by altering gene expression. Biochem. Biophys. Res. Commun. 310: 1227-1235.
72. SCRIBNER, A. W., J. LOSCALZO & C. NAPOLI. 2003. The effect of angiotensin-converting enzyme inhibition on endothelial function and oxidant stress. Eur. J. Pharmacol. 482: 95-99.
73. KOHLSTEDT, K., R.P. BRANDES, W. MULLER-ESTERL, et al. 2004. Angiotensin-converting enzyme is involved in outside-in signaling in endothelial cells. Circ. Res. 94: 60-67.
74. KOHLSTEDT, K., R. BUSSE & I. FLEMING. 2005. Signaling via the angiotensin-converting enzyme enhances the expression of cyclooxygenase-2 in endothelial cells. Hypertension 45: 126-132.